Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | MGLL | Q99685 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11905043 | 1.00 | SIRT6 (0.49) | SIRT6MAPTALDH1A1FAAHMGLL | |
| SCHEMBL6890515 | 0.88 | SIRT6 (0.53) | SIRT6MAPTALDH1A1KMT2ACYP1A2 | |
| SCHEMBL6888974 | 0.85 | MAPT (0.45) | SIRT6MAPTALDH1A1FAAHMGLL | |
| SCHEMBL6888004 | 0.85 | SIRT6 (0.50) | SIRT6MAPTALDH1A1FAAHMGLL | |
| SCHEMBL11905335 | 0.82 | SIRT6 (0.46) | SIRT6MAPTALDH1A1FAAHMGLL | |
| SCHEMBL11905342 | 0.82 | SIRT6 (0.46) | SIRT6MAPTALDH1A1FAAHMGLL | |
| SCHEMBL23122515 | 0.81 | MAPT (0.54) | SIRT6MAPTALDH1A1KMT2ACYP1A2 | |
| SCHEMBL29751836 | 0.81 | MAPT (0.54) | SIRT6MAPTALDH1A1KMT2ACYP1A2 | |
| SCHEMBL16103923 | 0.78 | SIRT6 (0.47) | SIRT6MAPTALDH1A1FAAHMGLL | |
| SCHEMBL6887531 | 0.77 | SIRT6 (0.54) | SIRT6MAPTALDH1A1FAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488520-B1 | CONDENSED AZINE-DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME (NL) | 2015-09-02 | — | — | EP | disclosed |
| US-8841289-B2 | Heterocyclic derivatives | MERCK SHARP & DOHME B.V. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | CHRNA5, CHRM5, CHRNA7 | SIRT6 377/4885MAPT 157/4885ALDH1A1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.